In the competitive landscape of the gastric cancer diagnostics market, advancements have propelled significant benefits. Innovative technologies such as liquid biopsy and AI-driven imaging enhance early detection accuracy, improving patient outcomes. These advancements also streamline diagnostic procedures, reducing turnaround time and enhancing efficiency in healthcare systems. Moreover, novel biomarkers and molecular profiling techniques offer personalized treatment insights, optimizing therapy selection and monitoring. Ultimately, these advancements foster early detection and contribute to tailored therapeutic approaches, enhancing overall patient care and prognosis in the challenging realm of gastric cancer diagnostics.
Data Bridge Market Research analyses that the Global Gastric Cancer Diagnostics Market size was valued at USD 1,053.96 million in 2022 and is expected to reach USD 1,950.82 million by 2030, registering a CAGR of 8% during the forecast period 2023 to 2030.
Below are the Top Five Gastric Cancer Diagnostics Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
F. Hoffmann-La Roche Ltd.
|
F. Hoffmann-La Roche Ltd. is a leading provider of diagnostic solutions for gastric cancer, offering a comprehensive range of tests and assays. Their innovative technologies enable early detection, precise diagnosis, and personalized treatment planning for gastric cancer patients. Roche's dedication to research and development ensures the continual improvement of diagnostic tools, contributing to better outcomes and quality of life for individuals affected by gastric cancer.
|
|
North America, Africa, Europe, Asia, and Oceania
|
In April 2019, F. Hoffmann-La Roche Ltd announced that it has launched its new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer. This new product launched by the company has increased its sales in the market.
|
|
2.
|
General Electric
|
General Electric's healthcare division offers diagnostic imaging technologies and molecular diagnostics for gastric cancer detection. Their state-of-the-art equipment and assays provide clinicians with valuable insights into diagnosing and managing gastric cancer. General Electric's commitment to research and innovation ensures the continual advancement of diagnostic capabilities for better patient care.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In August 2017, GE Healthcare (A subsidiary of GENERAL ELECTRIC COMPANY) announced a strategic partnership with ARTMS Products, Inc. for the QUANTM99TM Irradiation System (QISTM) for radioisotope production. This strategic partnership, the company increased its credibility in the market.
|
|
3.
|
BIOMÉRIEUX
|
BIOMÉRIEUX is a global leader in in vitro diagnostics, offering various diagnostic solutions for gastric cancer detection. Their innovative tests provide accurate and reliable results, aiding clinicians in early detection and treatment planning. BIOMÉRIEUX's commitment to research and development ensures cutting-edge technologies that contribute to the advancement of gastric cancer diagnostics.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
Oxford Nanopore Technologies plc announced a collaboration with bioMérieux to develop new infectious disease diagnostics. Together, they aim to enhance patient care through nanopore-based clinical research and in vitro diagnostic solutions. Nanopore sequencing, a pioneering technology, allows for analyzing lengthy DNA or RNA fragments. This technique involves monitoring alterations in electrical currents as nucleic acids traverse a protein nanopore, decoding signals to determine specific sequences.
|
|
4.
|
Myriad Genetics, Inc.
|
Myriad Genetics specializes in molecular diagnostic products for various diseases, including gastric cancer. Their gastric cancer diagnostics focus on genetic testing and molecular analysis to provide personalized treatment options. They offer innovative solutions to improve patient outcomes and guide physicians in making informed decisions.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In July 2018, Myriad Diagnotics, Inc. announced that it acquired Counsyl, Inc. to expand its product portfolio. This acquisition by the company has increased its position in women’s health genetic testing.
|
|
5.
|
Abbott
|
Abbott is renowned for its comprehensive portfolio of diagnostic products, including those for gastric cancer detection. Their advanced assays and instruments deliver precise results, enabling early detection and effective management of gastric cancer. Abbott's dedication to innovation and patient care drives its efforts to develop groundbreaking diagnostic solutions for better outcomes in gastric cancer patients.
|
|
Europe, Middle East and Africa, North America, South America, and Asia-Pacific
|
In February 2018, Abbott announced that it had signed an agreement with ANGLE plc to supply ANGLE with its PathVysion HER-2 DNA FISH Probe kits for ANGLE’s ANG-002 FDA study for FISH analysis of circulating tumor cells in the form of a research grant. This agreement by the company has increased its credibility in the market.
|
Conclusion
In conclusion, the gastric cancer diagnostics market is poised for significant growth driven by advances in diagnostic technologies, rising incidence rates, and increasing awareness campaigns. Key drivers include the growing adoption of minimally invasive procedures and the development of biomarker-based assays. In addition, expanding research efforts and healthcare infrastructure improvements present ample opportunities for market expansion. With these factors in play, the gastric cancer diagnostics market is positioned for robust growth in the coming years.
